[en] OBJECTIVES: : To test the usefulness of procalcitonin serum level for the reduction of antibiotic consumption in intensive care unit patients. DESIGN: : Single-center, prospective, randomized controlled study. SETTING: : Five intensive care units from a tertiary teaching hospital. PATIENTS: : All consecutive adult patients hospitalized for > 48 hrs in the intensive care unit during a 9-month period. INTERVENTIONS: : Procalcitonin serum level was obtained for all consecutive patients suspected of developing infection either on admission or during intensive care unit stay. The use of antibiotics was more or less strongly discouraged or recommended according to the Muller classification. Patients were randomized into two groups: one using the procalcitonin results (procalcitonin group) and one being blinded to the procalcitonin results (control group). The primary end point was the reduction of antibiotic use expressed as a proportion of treatment days and of daily defined dose per 100 intensive care unit days using a procalcitonin-guided approach. Secondary end points included: a posteriori assessment of the accuracy of the infectious diagnosis when using procalcitonin in the intensive care unit and of the diagnostic concordance between the intensive care unit physician and the infectious-disease specialist. MEASUREMENTS AND MAIN RESULTS: : There were 258 patients in the procalcitonin group and 251 patients in the control group. A significantly higher amount of withheld treatment was observed in the procalcitonin group of patients classified by the intensive care unit clinicians as having possible infection. This, however, did not result in a reduction of antibiotic consumption. The treatment days represented 62.6 +/- 34.4% and 57.7 +/- 34.4% of the intensive care unit stays in the procalcitonin and control groups, respectively (p = .11). According to the infectious-disease specialist, 33.8% of the cases in which no infection was confirmed, had a procalcitonin value >1microg/L and 14.9% of the cases with confirmed infection had procalcitonin levels <0.25 microg/L. The ability of procalcitonin to differentiate between certain or probable infection and possible or no infection, upon initiation of antibiotic treatment was low, as confirmed by the receiving operating curve analysis (area under the curve = 0.69). Finally, procalcitonin did not help improve concordance between the diagnostic confidence of the infectious-disease specialist and the ICU physician. CONCLUSIONS: : Procalcitonin measuring for the initiation of antimicrobials did not appear to be helpful in a strategy aiming at decreasing the antibiotic consumption in intensive care unit patients.
Disciplines :
Anesthésie & soins intensifs
Auteur, co-auteur :
LAYIOS, Nathalie ; Centre Hospitalier Universitaire de Liège - CHU > Soins intensifs
LAMBERMONT, Bernard ; Centre Hospitalier Universitaire de Liège - CHU > Frais communs médecine
CANIVET, Jean-Luc ; Centre Hospitalier Universitaire de Liège - CHU > Soins intensifs
MORIMONT, Philippe ; Centre Hospitalier Universitaire de Liège - CHU > Frais communs médecine
Kollef MH, Fraser VJ: Antibiotic resistance in the intensive care unit. Ann Intern Med 2001; 134:298-314. (Pubitemid 32163954)
Kumar A, Roberts D, Wood KE, et al: Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34:1589-1596. (Pubitemid 43810035)
Leone M, Bourgoin A, Cambon S, et al: Empirical antimicrobial therapy of septic shock patients: adequacy and impact on the outcome. Crit Care Med 2003; 31:462-467. (Pubitemid 36232941)
Goldmann DA, Weinstein RA, Wenzel RP, et al: Strategies to prevent and control the emergence and spread of antimicrobialresistant microorganisms in hospitals. A challenge to hospital leadership. JAMA 1996; 275:234-240. (Pubitemid 26028565)
Dellit TH, Owens RC, McGowan JE Jr, et al; Infectious Diseases Society of America; Society for Healthcare Epidemiology of America: Infectious Diseases Society of America and the Society for Healthcare Epidemiology Figure.
Discrimination power of procalcitonin (PCT) levels. The outcome was diagnosis of infection assessed by infectious-disease specialist as sure or probable. The area under the receiving operating curve was 0.69. of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007; 44:159-177.
Limper M, de Kruif MD, Duits AJ, et al: The diagnostic role of procalcitonin and other biomarkers in discriminating infectious from non-infectious fever. J Infect 2010; 60:409-416.
Christ-Crain M, Jaccard-Stolz D, Bingisser R, et al: Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 2004; 363:600-607. (Pubitemid 38264177)
Christ-Crain M, Stolz D, Bingisser R, et al: Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: A randomized trial. Am J Respir Crit Care Med 2006; 174:84-93. (Pubitemid 43955248)
Stolz D, Christ-Crain M, Bingisser R, et al: Antibiotic treatment of exacerbations of COPD: A randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest 2007; 131:9-19. (Pubitemid 46122969)
Müller B, Becker KL, Schächinger H, et al: Calcitonin precursors are reliable markers of sepsis in a medical intensive care unit. Crit Care Med 2000; 28:977-983. (Pubitemid 30262065)
Moreno R, Vincent JL, Matos R, et al: The use of maximum SOFA score to quantify organ dysfunction/failure in intensive care. Results of a prospective, multicentre study. Working Group on Sepsis related Problems of the ESICM. Intensive Care Med 1999; 25:686-696. (Pubitemid 29376122)
American College of Chest Physican/Society of Critical Care medicine Consensus Conference Committee: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20:864-874.
ATC/DDD Index 2011: WHO Collaborating Centre for Drug Statistics Methodology. Available at: http://www.whocc.no/atc-ddd- index/. Accessed August 1, 2011.
Bouadma L, Luyt CE, Tubach F, et al; PRORATA trial group: Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): A multicentre randomised controlled trial. Lancet 2010; 375:463-474.
Jung B, Embriaco N, Roux F, et al: Microbiogical data, but not procalcitonin improve the accuracy of the clinical pulmonary infection score. Intensive Care Med 2010; 36:790-798.
Luyt CE, Combes A, Reynaud C, et al: Usefulness of procalcitonin for the diagnosis of ventilator-associated pneumonia. Intensive Care Med 2008; 34:1434-1440.
Pelosi P, Barassi A, Severgnini P, et al: Prognostic role of clinical and laboratory criteria to identify early ventilator-associated pneumonia in brain injury. Chest 2008; 134:101-108. (Pubitemid 352008770)
Nobre V, Harbarth S, Graf JD, et al: Use of procalcitonin to shorten antibiotic treatment duration in septic patients: A randomized trial. Am J Respir Crit Care Med 2008; 177:498-505. (Pubitemid 351442188)
Hausfater P, Juillien G, Madonna-Py B, et al: Serum procalcitonin measurement as diagnostic and prognostic marker in febrile adult patients presenting to the emergency department. Crit Care 2007; 11:R60.
Jensen JU, Hein L, Lundgren B, et al; for The Procalcitonin and Survival Study (PASS) Group: Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: A randomized trial. Crit Care Med 2011; 39:2048-2058.